This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00382239
First received: September 26, 2006
Last updated: February 20, 2015
Last verified: January 2015
September 26, 2006
February 20, 2015
September 2006
May 2007   (Final data collection date for primary outcome measure)
Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]
Assess dose response effect on glucose control as measured by HbA1c among four doses (2.5 μg, 5 μg, 10 μg, and placebo) of subcutaneous injection of exenatide, twice daily before meals in the morning and evening, for 12 weeks
To assess the effect on glucose control (as measured by HbA1c) of LY2148568 (exenatide).
Complete list of historical versions of study NCT00382239 on ClinicalTrials.gov Archive Site
  • Proportion of subjects achieving HbA1c <7% at Week 12 [ Time Frame: 12 weeks ]
    Total number of subjects achieving HbA1c <7% at Week 12
  • Changes in fasting blood glucose from Visits 3 to 7 [ Time Frame: Baseline, Week 12 ]
    Changes in fasting blood glucose from Baseline (Visit 3) to Week 12 (Visit 7)
  • Change in Serum lipids from Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]
    Changes in serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) from Baseline (Visit 3) to Week 12 (Visit 7)
  • Changes in body weight, waist size and waist/hip ratio from Baseline to Week 12 [ Time Frame: Baseline, Week 12 ]
    Changes in body weight, waist size and waist/hip ratio from Baseline (Visit 3) to Week 12 (Visit 7)
To assess the effect of LY2148568 (exenatide) on the following items: *proportion of patients achieving HbA1c <7%; *fasting glucose; *body weight; *treatment emergent adverse events; *various pharmacokinetic and pharmacodynamic parameters.
Not Provided
Not Provided
 
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled
This study will examine the response of several doses of LY2148568 (exenatide) and assess the effect on glucose control and safety and tolerability in Japanese patients with type 2 diabetes.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: exenatide (LY2148568)
    subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
    Other Name: Byetta
  • Drug: exenatide (LY2148568)
    subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
    Other Name: Byetta
  • Drug: exenatide (LY2148568)
    subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
    Other Name: Byetta
  • Drug: Placebo
    subcutaneous injection twice daily, 0.02 mL to 0.04 mL
  • Experimental: Exenatide 5 mcg/exenatide 10 mcg
    Intervention: Drug: exenatide (LY2148568)
  • Experimental: Exenatide 5 mcg/exenatide 5 mcg
    Intervention: Drug: exenatide (LY2148568)
  • Experimental: Exenatide 2.5 mcg/exenatide 2.5 mcg
    Intervention: Drug: exenatide (LY2148568)
  • Placebo Comparator: Placebo/placebo
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
153
May 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with type 2 diabetes.
  • Have a body weight of >=50 kg.

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Have participated in this study previously, or any other study using exenatide or other GLP-1 analogs.
  • Are treated with any exogenous insulin within 3 months of screening.
  • Are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): *drugs that directly affect gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan® (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride), or Cerekinon® (trimebutine).
  • Have characteristics contraindicating for concomitant medication, according to product-specific label.
  • Have severe allergy or hypersensitivity to any drug.
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00382239
H8O-JE-GWAV
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Eli Lilly and Company
Study Director: James Malone, MD Eli Lilly and Company
AstraZeneca
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP